A clinical-stage biotech firm developing next-generation antibody therapies for severe inflammatory bowel diseases utilizing a unique small molecule-derived antibody platform.
Early-stage biotech investors may find value in TuHURA due to its novel TuH129 platform targeting the large and lucrative IBD market with few direct competitors. The company's recent capital raise provides a runway to complete critical clinical milestones, potentially unlocking significant value upon successful regulatory approval.
The stock carries extreme risk given the total absence of revenue and a substantial accumulated deficit of $111.1M that must be covered by future equity issuances. Investors should exercise caution as the company faces a binary outcome scenario where clinical failure would likely result in near-total asset liquidation.
TuHURA Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for severe inflammatory diseases such as Crohn's disease and ulcerative colitis. The company leverages its proprietary TuH129 antibody platform to target specific immune pathways, aiming to address significant unmet medical needs in the gastroenterology market.
Despite reporting a net loss of $21.7M and negative operating cash flow of $14.7M, the company successfully secured $29.8M in financing cash flows, resulting in a strong positive net change in cash position. Management has prioritized R&D spending of $13.3M to advance clinical candidates, while maintaining a conservative balance sheet with current assets of $19.6M against only $5.3M in current liabilities.
The global inflammatory bowel disease market is valued in the billions and is experiencing growth due to an aging population and increased diagnosis rates, yet existing treatments often suffer from limited efficacy or severe side effects. TuHURA aims to disrupt this landscape by offering targeted therapies that provide better patient outcomes compared to current standard-of-care biologics.
| Metric | 2024 |
|---|---|
| Revenue | $0 |
| Cost of Revenue | $0 |
| Gross Profit | $0 |
| Operating Expenses | $-21.7M |
| Operating Income | $21.7M |
| R&D | $13.3M |
| G&A | $4.3M |
| Stock-Based Comp | $2.0M |
| D&A | $116.7K |
| Depreciation | $117.0K |
| Other OpEx | $-39.3M |
| Non-Operating Income | $0 |
| Interest Expense | $4.1M |
| Interest Income | $361.6K |
| Pre-Tax Income | $21.7M |
| Income Tax | $3.8K |
| Continuing Ops | $21.7M |
| Discontinued Ops | $-43.4M |
| Net Income | $-21.7M |
| Minority Interest | $0 |
| Net to Common | $-21.7M |
| Metric | 2024 |
|---|---|
| Current Assets | $19.6M |
| Cash & Equivalents | $12.7M |
| Other Current Assets | $7.0M |
| Long-Term Assets | $356.3K |
| PP&E (Net) | $123.4K |
| Operating Leases | $199.2K |
| Other LT Assets | $33.8K |
| Total Assets | $20.0M |
| Current Liabilities | $5.3M |
| Accounts Payable | $3.2M |
| Current Leases | $159.8K |
| Other Current Liab | $855.7K |
| Long-Term Liabilities | $42.7K |
| LT Operating Leases | $42.7K |
| Other LT Liab | $0 |
| Total Liabilities | $5.4M |
| Shareholders' Equity | $14.6M |
| Retained Earnings | $-111.1M |
| Total L&E | $20.0M |
| Metric | 2024 |
|---|---|
| Net Income (CFO) | $-21.7M |
| Non-Cash Adjustments | $3.0M |
| Working Capital Changes | $4.0M |
| Cash from Operations | $-14.7M |
| Capital Expenditures | $57.9K |
| Cash from Investing | $-6.1M |
| Cash from Financing | $29.8M |
| FX Effect | $0 |
| Net Change in Cash | $9.0M |
| Beginning Cash | $3.7M |
| Ending Cash | $12.7M |
The company operates primarily through its drug discovery and development segment, focusing on the TuH129 program for IBD. Additional segments include strategic licensing and collaboration activities where the company may provide intellectual property or manufacturing services to external partners, though current revenue is nil as operations are pre-commercialization.
The company has generated no revenue to date, making it entirely dependent on successful clinical trial outcomes and future fundraising capabilities. Significant dilution risk exists as the cash burn rate is high relative to available liquidity, requiring frequent capital raises that may impact existing shareholders. The highly competitive nature of the IBD market poses a threat to potential market share if competitors secure regulatory approval faster or offer superior efficacy profiles.
TuHURA possesses a differentiated small molecule-derived antibody platform (TuH129) that offers high potency and selectivity against inflammatory targets. The company maintains significant financial flexibility with $12.7M in cash and recent financing proceeds to fund clinical trials without immediate revenue pressure. A lean operational structure with minimal fixed assets allows for agile decision-making in early-stage development.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.